BECTON, DICKINSON AND COMPANY

The U.S. disposable syringes market is projected to reach USD 3.69 billion by 2030 with a 5.5% CAGR, driven by rising vaccine demand, self-administered drug solutions, safety syringe adoption, and technological advancements. The COVID-19 pandemic significantly boosted demand for U.S.-made disposable syringes, with UNICEF aiming to purchase 1 billion auto-disable syringes by 2021 for COVAX nations. Safety syringes and therapeutic injections dominate the market, with California expected to see the fastest growth due to an aging population and increased healthcare expenditure.

The Medical Nanotechnology Market is projected to reach $334.7 billion by 2032, driven by advancements in diagnostics, drug delivery, and tissue engineering. Key players include Siemens Healthineers, GE Healthcare, and Johnson & Johnson. Market growth is fueled by personalized medicine, chronic disease treatment, and increased R&D investments.

Global cell culture market to reach $36,926.80 million by 2027, with a CAGR of 10.9%. Increased awareness and research in cancer and COVID-19 drive demand. Market segmented by product, application, end user, and region. Key players include Becton, Dickinson and Company, Corning Incorporated, and Thermo Fisher Scientific.

QIAGEN launches PAXgene Urine Liquid Biopsy Set, enabling non-invasive cfDNA analysis from urine with standardized preanalytical workflow, complementing existing liquid biopsy solutions.

The INTREPID trial found that a temperature management machine reduced fever risk in ICU stroke patients but did not improve functional outcomes. The study, published in JAMA, suggested several reasons for the neutral results, including patient intolerance and varying ICU care needs. The trial was stopped early for futility, and further investigation is needed to determine if fever prevention benefits specific patient groups.

The global cell expansion market is projected to grow at a CAGR of 12.1% from 2024 to 2034, reaching $40.1 billion by 2034. AI and ML are revolutionizing the process, while decentralized healthcare drives portable technologies. Key players include Thermo Fisher Scientific, Miltenyi Biotec, and Merck KGaA. Stem cells and bioreactors dominate the market, with biotechnology and pharmaceutical companies leading in end-user segments. North America and Europe are major regions, with Asia Pacific witnessing rapid growth.

The Cell Based Assays Market is projected to grow from USD 20.42 Billion in 2023 to USD 39.23 Billion by 2031, driven by pharmaceutical R&D, technological advancements, personalized medicine, and reduced animal testing. Key challenges include high costs, complexity, and technical limitations. Trends include 3D cell culture, AI integration, precision medicine, and immuno-oncology. North America leads the market, followed by Asia Pacific and Europe.

Stem Cell Manufacturing Market to reach USD 28.8 Billion by 2031, driven by regenerative medicine advancements, regulatory support, and a CAGR of 12.3%. North America leads, followed by Europe and Asia Pacific. Challenges include high operational costs and stringent regulations.

The ultrasound and electrosurgical energy dissectors market is projected to reach $8.48 billion by 2028 with a CAGR of 7.1%, driven by factors like point-of-care diagnostics, robotic surgeries, and outpatient procedures. Key players include Johnson & Johnson, Medtronic, and Olympus Corporation. Market segments include ultrasound and electrosurgical devices, applications in cardiology, gynecology, and general surgery, and end-users such as hospitals and ambulatory surgical centers.

The global Life Science Instrumentation market is projected to grow from $75.9B in 2023 to $104B by 2030, driven by technological innovations, personalized medicine, and high-throughput screening. Key players include Agilent Technologies, Becton Dickinson, and Bio-Rad Laboratories. The report provides comprehensive market analysis, regional insights, and company profiles.